BioNTech Shares Surge 2070% in Two Days Trading Volume Ranks 245th

BioNTech(BNTX) shares rose 2.25% on June 3, 2025, marking the second consecutive day of gains, with a total increase of 20.70% over the past two days. The trading volume for the day was 3.82 billion, a 35.78% decrease from the previous day, ranking 245th in the overall market.

BioNTech has entered into a strategic partnership with Bristol Myers Squibb to co-develop and co-commercialize its next-generation bispecific antibody candidate, BNT327. This collaboration aims to accelerate the development of BNT327, which targets PD-L1 and VEGF-A, across multiple solid tumor types. The agreement includes a 50/50 profit/loss split and leverages the expertise and resources of both companies to expedite the path towards potential regulatory approvals and market launches.

BNT327 is currently being evaluated in multiple ongoing trials, including global Phase 3 trials for extensive stage small cell lung cancer and non-small cell lung cancer. Preliminary data from these trials suggest that combining anti-PD-L1 and anti-VEGF-A into a single molecule could deliver synergistic clinical benefits for patients across various tumor types. The companies will jointly develop and commercialize BNT327, with both having the right to independently develop it in further indications and combinations.

Prof. Ugur Sahin, CEO and Co-Founder of BioNTech, expressed optimism about BNT327's potential to become a foundational immuno-oncology backbone, moving beyond single-mechanism checkpoint inhibitors and expanding into multiple solid-tumor indications. The collaboration with Bristol Myers Squibb is expected to accelerate and broaden the development of BNT327, complementing BioNTech's existing antibody-drug conjugate programs and mRNA-based immunotherapies.